Diagnostic pitfalls in digestive neuroendocrine tumours.
Acta Gastroenterol Belg
; 72(1): 29-33, 2009.
Article
em En
| MEDLINE
| ID: mdl-19402368
ABSTRACT
Gastro-entero-pancreatic neuroendocrine tumours (GEP NET) represent a rare and highly heterogeneous entity that often is revealed by vague and non-specific symptoms, leading to a delayed diagnosis. Here we will review some of the most regularly observed false positive and false negative cases and provide clues to recognize and manage them properly. Particularly, the value of chromogranin-A as a serum tumour marker and Somatostatin receptor scintigraphy as an imaging test, are reviewed. Indeed, chromogranin-A and other hormones, such as gastrin, as well as urinary 5-hydroxy-indolic acetic acid (5-HIAA) are often tested to diagnose NET without appraising the clinical situation, leading to extensive work-up on false bases. On the other hand, some tests are performed in situations where they do not add additional information (e.g. 5-HIAA in pancreatic or rectal NET) because invariably negative. Somatostatin receptor scintigraphy is an expensive examination, still not reimbursed in Belgium, for which indications must be carefully assessed, knowing its specificity and sensitivity.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Tumores Neuroendócrinos
/
Neoplasias do Sistema Digestório
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Revista:
Acta Gastroenterol Belg
Ano de publicação:
2009
Tipo de documento:
Article